A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate the earliest stages of the disease.
[More]
A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer.
[More]
Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference in Philadelphia, PA, May 17 – 22.
[More]
Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).
[More]
Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.
[More]
Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a clinical guide by the European Menopause and Andropause Society in the journal Maturitas on endometrial assessment in peri and postmenopausal women with summary recommendations.
[More]
Exelixis, Inc. announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology.
[More]
A new class of drug targeting skin cancer's genetic material has been successfully tested in humans for the first time, opening the way to new treatments for a range of conditions from skin cancers to eye diseases.
[More]
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1b/2a clinical study of ISIS-STAT3Rx in patients with advanced metastatic hepatocellular carcinoma (HCC).
[More]
In an effort to better protect women from heart disease, Irene Pollin, a widely respected public health advocate who founded the nation's first organization dedicated to preventing heart disease in women, has donated $10 million to the Barbra Streisand Women's Heart Center at the Cedars-Sinai Heart Institute.
[More]
deCODE genetics (an Amgen subsidiary) and Illumina, global leaders in analyzing and understanding the human genome, together with scientists from the National Hospital of Iceland and the University of Iceland reported today in the journal Nature the identification of a rare nonsense mutation that confers high risk of osteoporosis and osteoporosis related traits.
[More]
Cancer Genetics, Inc., a leader in oncology-focused personalized medicine, has launched a proprietary urogenital cancer array, UroGenRA, intended for kidney cancer diagnosis and subtyping in its own laboratory.
[More]
The ductal carcinoma in situ Score quantifies the risk of ipsilateral breast event and invasive IBE risk, complements both traditional clinical and pathologic factors, and helps provide a new clinical tool to improve the process of selecting individualized treatment for women with DCIS who meet the criteria, according to a study published May 2 in the Journal of the National Cancer Institute.
[More]
Solving the structure of a critical human molecule involved in cancer, scientists at The Scripps Research Institute have found what they call a good example of structural conservation-dissimilar genes that keep very similar shapes.
[More]
Because members of Congress are accustomed to high-quality medical care provided to them through federal employee benefit programs, one might expect that they would push for top quality care to be delivered through the exchanges too.
[More]
The most in-depth look yet at endometrial cancer shows that adding genomics-based testing to the standard diagnostic workup could change the recommended course of treatment for some women.
[More]
Two studies from The Cancer Genome Atlas program reveal details about the genomic landscapes of acute myeloid leukemia and endometrial cancer.
[More]
Researchers have provided new evidence that could act as a guide for the use of radioiodine therapy after patients have undergone radiographic imaging studies that use iodine as a contrasting agent.
[More]
The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology.
[More]
Surgery is often recommended for skin cancers, but older, sicker patients can endure complications as a result and may not live long enough to benefit from the treatment.
[More]